Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$27,000.00

Developing a Novel Vaccine Platform to Induce Antibodies Against Peptide-Major Histocompatibility Complexes (MHC) II

FY 2024-25

Summary
Celiac disease (CD) is an autoimmune disorder triggered by gluten, a protein found in wheat, barley, and rye. When individuals with CD consume gluten, their immune system mistakenly attacks the lining of their gastrointestinal tract, leading to inflammation and damage. This damage impairs the body's ability to absorb essential nutrients, causing a range of health problems. Currently, about 300,000 Canadians are affected by CD, with incidence rates continuing to rise. With the only available treatment being a strict gluten-free diet, CD poses a significant healthcare burden. In CD, the immune system's attack on the intestine occurs in two stages. First, certain immune cells that interact with gluten activate other immune cells called T cells. These activated T cells then stimulate B cells, which produce antibodies. Unfortunately, in CD, these antibodies mistakenly target the body's own proteins, causing further damage. Our research aims to develop a vaccine that helps the body produce unique antibodies designed to block these harmful interactions between immune cells. By doing so, we hope to stop the production of damaging antibodies and offer a new treatment option for CD. The first phase of our project involves creating a new type of antigen;a substance that triggers an immune response;specifically designed to target certain immune cells. We will test this vaccine in mice to see if it can lead to the production of unique antibodies and prevent the harmful immune response seen in CD. If successful, this innovative approach could pave the way for developing effective treatments for CD. Moreover, this vaccine offers a new framework for designing potent immunotherapies for other autoimmune diseases.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
529947
Name
Mriduraj Angitha
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Developing a Novel Vaccine Platform to Induce Antibodies Against Peptide-Major Histocompatibility Complexes (MHC) II
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Autoantibodies (Autoabs); Autoimmune Disorder; Cd4 T Cells; Celiac Disease (Cd); Dendritic Cells (Dcs); Enzyme-Linked Immunosorbent Assay (Elisa); Major Histocompatibility Complex (Mhc) Ii; T Cell Receptor (Tcr); Tcr-Like (Tcrl) Antibodies (Abs); Vaccine
Abstract
Celiac disease (CD) is an autoimmune disorder triggered by gluten, a protein found in wheat, barley, and rye. When individuals with CD consume gluten, their immune system mistakenly attacks the lining of their gastrointestinal tract, leading to inflammation and damage. This damage impairs the body's ability to absorb essential nutrients, causing a range of health problems. Currently, about 300,000 Canadians are affected by CD, with incidence rates continuing to rise. With the only available treatment being a strict gluten-free diet, CD poses a significant healthcare burden. In CD, the immune system's attack on the intestine occurs in two stages. First, certain immune cells that interact with gluten activate other immune cells called T cells. These activated T cells then stimulate B cells, which produce antibodies. Unfortunately, in CD, these antibodies mistakenly target the body's own proteins, causing further damage. Our research aims to develop a vaccine that helps the body produce unique antibodies designed to block these harmful interactions between immune cells. By doing so, we hope to stop the production of damaging antibodies and offer a new treatment option for CD. The first phase of our project involves creating a new type of antigen;a substance that triggers an immune response;specifically designed to target certain immune cells. We will test this vaccine in mice to see if it can lead to the production of unique antibodies and prevent the harmful immune response seen in CD. If successful, this innovative approach could pave the way for developing effective treatments for CD. Moreover, this vaccine offers a new framework for designing potent immunotherapies for other autoimmune diseases.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mriduraj, Angitha
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~